Key Takeaway: Vor Bio, a clinical-stage biotechnology company, has announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The company will present and host one-on-one investor meetings on January 13, 2026. Vor Bio is focused on advancing its novel dual-target fusion protein, telitacicept, through Phase 3 development aimed at treating autoimmune diseases. The presentation will be available via a live webcast, enhancing investor engagement.
Price reaction · baseline $10.58 (2026-01-05 close) · hit after-hours · clean, no other VOR news in the window
day 0 close
+10.3%
day 1 · peak
+28.2%
day 3
+27.8%
Market Sentiment Analysis
POSITIVE FACTORS
Vor Bio is actively participating in a major healthcare conference, indicating engagement with the investment community.
The company is focusing on advancing telitacicept through Phase 3 clinical development, a key step towards commercialization.
The presentation will be made available via live webcast, increasing transparency and accessibility for investors.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+442%
120-day peak, hindsight
Typical move
18.8%
average across 6 past catalysts
Cash runway
~55 mo
Minimal dilution risk
Lead asset
Telitacicept
Phase 3 · Primary Sjogren's Disease
Full Press Release Details
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Presentation: Tuesday, January 13, 2026 at 10:30am – 11:10 am PT
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
Media & Investor Contacts:
Frequently Asked Questions
What event is Vor Bio participating in?
Vor Bio will participate in the 44th Annual J.P. Morgan Healthcare Conference.
When will Vor Bio's presentation take place?
The presentation is scheduled for January 13, 2026, from 10:30 to 11:10 am PT.
How can I watch Vor Bio's presentation?
You can watch the presentation live or access the replay on their website.
What is the focus of Vor Bio's developments?
Vor Bio is focused on advancing telitacicept for autoimmune disease treatment.
Where is the J.P. Morgan Healthcare Conference held?
The conference will be held at The Westin St. Francis in San Francisco, CA.